Bi-Functional Peptides for Multiple Sclerosis Treatment and Diagnosis

Track Code: 
The invention consists of new bi-functional protein inhibitors (“BPIs”) for treatment and diagnostics of autoimmune diseases such as MS and experimental autoimmune encephalomyelitis. The novel BPIs are capable of modulating the immune response towards a TH2 response.

Multiple sclerosis (“MS”) is the autoimmune disease of the central nervous systems, including brain, spinal cord, and optic nerves due to damage of the myelin, the fatty tissue surrounding nerve fibers that helps the nerve conduct electric impulses.  The attack of myelin by the immune system is due to the activation of a subpopulation of T-cells that recognize a specific antigen from proteins in myelin.

            A defining stage in immune response is the differentiation of CD4+ T-cells into either type-1 helper T-cells (TH1) or type-2 helper T-cells (TH2).  Differentiation into TH1 cells predominantly results in cell-mediated immunity while differentiation into TH2 cells predominantly results in humoral immunity.  TH1 dominant immunity protects the body against intracellular pathogens (e.g. bacteria) but is also implicated in autoimmune diseases.

How it works: 
The invention is a therapeutic molecule that facilitates switch from TH1 dominant immunity to TH2 responses, a major goal in the modern treatment of autoimmune diseases like MS and transplant rejection.
  •  BPIs are novel molecular entities.
  •  BPIs switch from TH1 dominant immunity to TH2 responses.
  •  BPIs can quickly diagnose MS by aid of MRI.
Other Applications: 
  • Autoimmune disorders.
  • Rapid diagnosis of MS by MRI.
Licensing Associate: 
Aswini Betha, PhD · · 913-588-5713
US 8,188,218